Literature DB >> 22183109

Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?

Laura Evangelista, Domenico Rubello, Giorgio Saladini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22183109     DOI： 10.1007/s00259-011-2018-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  24 in total

1.  Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

Authors:  Nina Mortazavi-Jehanno; Anne-Laure Giraudet; Laurence Champion; Florence Lerebours; Elise Le Stanc; Veronique Edeline; Olivier Madar; Dominique Bellet; Alain Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

2.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

Authors:  Hannah M Linden; Svetlana A Stekhova; Jeanne M Link; Julie R Gralow; Robert B Livingston; Georgiana K Ellis; Philip H Petra; Lanell M Peterson; Erin K Schubert; Lisa K Dunnwald; Kenneth A Krohn; David A Mankoff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

Authors:  J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

4.  Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer.

Authors:  Olivier Couturier; Guy Jerusalem; Jean-Michel N'Guyen; Roland Hustinx
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

5.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

6.  A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Authors:  U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

7.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?

Authors:  T Jansson; J E Westlin; H Ahlström; A Lilja; B Långström; J Bergh
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

8.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

Review 9.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

10.  Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer.

Authors:  Paula Lindholm; Maria Lapela; Kjell Någren; Pertti Lehikoinen; Heikki Minn; Sirkku Jyrkkiö
Journal:  Nucl Med Commun       Date:  2009-01       Impact factor: 1.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.